Methamphetamine Dependence Clinical Trial
Official title:
Pilot Study of the Dose Response of Entacapone on Methamphetamine Induced Interest, Mood Elevation, and Reward
Addiction to methamphetamine is a serious health problem. There are no medications that a
doctor can give someone to help them stop using methamphetamine. Entacapone (Comtan©) is a
medication that could help people addicted to methamphetamine.
This study will see how entacapone works in healthy people who are given methamphetamine. We
think that the study drug will be well tolerated, and that it will prevent some of the
effects of methamphetamine that make it so addictive. We also want to see how differences in
people's genes may cause differences in the ways the study drug and methamphetamine work for
them.
The study has six total visits. The first visit is for screening. Tests and procedures will
make sure it is safe for subjects to participate.
The second visit is a familiarization day. Subjects will receive methamphetamine, but no
entacapone. This is done to make sure they can tolerate the drug and recognize its effects
before being given a second drug on the same day. Subjects will take surveys and computer
tests to see how the medications change mood, thinking, and liking the drug.
The final four visits are the actual study days. Subjects will be randomly assigned (like the
flip of a coin) to the different ways to get either 1) study medication or placebo (placebo
contains no active study medication) and then 2) methamphetamine or placebo. Subjects will be
in all four groups during the study, which means that each day a subject will get a different
group.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01813656 -
An Study of Aripiprazole in the Treatment of Methamphetamine Dependence
|
Phase 4 | |
| Completed |
NCT00984360 -
Study of Naltrexone for Methamphetamine Addiction
|
Phase 2 | |
| Completed |
NCT01685463 -
Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving
|
N/A | |
| Completed |
NCT00569374 -
Safety and Tolerability of Modafinil for Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01967381 -
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
|
Early Phase 1 | |
| Completed |
NCT01354470 -
A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
|
Phase 2 | |
| Active, not recruiting |
NCT01044238 -
Methylphenidate to Treat Methamphetamine Dependence
|
Phase 2 | |
| Terminated |
NCT01019707 -
Safety Assessment of Atomoxetine With MA IV Administration
|
Phase 1 | |
| Completed |
NCT01215929 -
Studying Amphetamine Withdrawal in Humans
|
Phase 2 | |
| Completed |
NCT00227123 -
A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence
|
N/A | |
| Recruiting |
NCT02568878 -
Creatine for Depressed Male and Female Methamphetamine Users
|
Phase 3 | |
| Completed |
NCT01011829 -
Varenicline vs Placebo for the Treatment of Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01007539 -
Efficacy and Safety of CDP-choline in Patients With Methamphetamine Dependence
|
Phase 3 | |
| Completed |
NCT01062451 -
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Completed |
NCT00687713 -
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01063205 -
NAC as a Potential Treatment for Methamphetamine Dependence
|
Phase 1 | |
| Completed |
NCT00332605 -
N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence
|
Phase 2 | |
| Completed |
NCT01860807 -
Trial of Ibudilast for Methamphetamine Dependence
|
Phase 2 | |
| Terminated |
NCT01813643 -
A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis
|
Phase 4 | |
| Completed |
NCT01073319 -
Rivastigmine as a Treatment for Methamphetamine Dependence
|
Phase 1 |